Recombinant human interferon α2b injection

Pharmacology: Recombinant human interferon α2b has broad-spectrum antiviral, anti-tumor, cell proliferation inhibition and immune function enhancement effects. Interferon binds to cell surface receptors to induce cells to produce a variety of antiviral proteins, inhibit viral reproduction in cells, and improve immune function, including enhancing the phagocytic function of macrophages, enhancing the cytotoxicity of lymphocytes to target cells and the function of natural killer cells. Toxicology: Acute toxicity test: Mice were injected intraperitoneally and intravenously with doses of 1.5×109 international units (IU)/kg and 1.5×108 international units (IU)/kg, respectively, which are 105 times and 104 times the therapeutic dose for humans. No acute poisoning symptoms occurred and no animals died. Long-term toxicity test: Rats were injected intramuscularly with this product, the dose

The main ingredient of this product is recombinant human interferon α2b, and the auxiliary materials are human albumin, sodium chloride and mannitol. Its main ingredient, recombinant human interferon α2b, is made from Escherichia coli containing highly efficient expression of human interferon α2b gene, after fermentation, separation and high purification.

It should be a white, thin, loose shell. After adding 1 ml of water for injection, it should quickly dissolve into a clear liquid.

1. Used to treat certain viral diseases, such as acute and chronic viral hepatitis, herpes zoster, and genital warts. 2. Used to treat certain tumors, such as hairy cell leukemia, chronic myeloid leukemia, multiple myeloma, non-Hodgkin's lymphoma, malignant melanoma, renal cell carcinoma, laryngeal papilloma, Kaposi's sarcoma, ovarian cancer, basal cell carcinoma, superficial bladder cancer, etc.

This product can be injected intramuscularly, subcutaneously and into lesions. Reconstitute with 1 ml of water for injection before use. 1. Chronic hepatitis B: Subcutaneous or intramuscular injection, once a day, the recommended dose is 3-6 million international units (IU). After four weeks of continuous use, change to 3 times a week for more than 16 weeks. The doctor can adjust the dose according to the patient's specific circumstances. 2. Acute and chronic hepatitis C: Subcutaneous or intramuscular injection, once a day, the recommended dose is 3-6 million international units (IU) each time. After four weeks of continuous use, change to 3 times a week for more than 16 weeks. The doctor can adjust the dose according to the patient's specific circumstances. 3. Herpes zoster: Intramuscular injection, once a day, 1 million IU each time

Common symptoms of this product include fever, headache, chills, fatigue, myalgia, and joint pain, which often occur in the first week of medication. Most adverse reactions disappear after 48 hours of injection. In case of serious adverse reactions, the treatment plan must be modified or the medication must be stopped. If an allergic reaction occurs, the medication should be stopped immediately. A small number of patients may also experience blood abnormalities such as leukopenia and thrombocytopenia, which will return to normal after stopping the medication. Occasionally, there are adverse reactions such as anorexia, nausea, diarrhea, vomiting, hair loss, high (or low) blood pressure, and nervous system disorders. References: Other adverse reactions of alpha interferon reported in the literature include: diarrhea, nausea, hypertension, hypotension, vomiting, joint pain, impaired perception, mental confusion, dizziness, movement disorders, paresthesia, anxiety, depression, tension

1. Those with a history of allergy to recombinant human interferon α2b or any of its ingredients. 2. Those with severe heart disease. 3. Those with severe liver, kidney and bone marrow dysfunction. 4. Those with epilepsy and central nervous system damage. 5. Those with other serious diseases who cannot tolerate this product should not use it.

Precautions for children: There is still limited experience with medication in children. For such cases, the drug should be used in accordance with the doctor's instructions after carefully weighing the pros and cons. Precautions for pregnancy and lactation: There is limited experience with medication in pregnant women, and the method of safely using this product during pregnancy has not yet been established. Therefore, injections for pregnant women must be made when the condition is very necessary and after careful consideration by the clinician. Precautions for the elderly: For elderly patients with heart disease and elderly patients with advanced cancer, electrocardiograms should be performed before and during treatment with this agent, and the dose should be adjusted or the drug should be stopped according to the doctor's instructions.

Interferon may change the activity of some enzymes, especially reduce the activity of cytochrome P450, thus affecting the metabolism of drugs such as cimetidine, warfarin, theophylline, diazepam, and propranolol. When used in combination with drugs with central effects, interactions may occur.

Store and transport at 2-8℃ away from light. The validity period is 30 months from the date of packaging.

0.6ml: 6 million IU (prefilled syringe)

The validity period is 24 months from the date of packaging.

Beijing Kawin Technology Share-Holding Co., Ltd.

• Founded in:

  2008-08-20

• Address:

  Building 3, No. 6, Rongjing East Street, Beijing Economic and Technological Development Zone, Beijing

• Tax NO.:

  911103026787533566

• Registered Funds:

  170.944422 million yuan

• Website:

  Log in to view

• Email:

  Log in to view